Publications

April 2018
2018 American Association for Cancer Research (AACR) Annual Meeting
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Enhances Immune Cell Infiltration and Activation in the Tumor Microenvironment of Melanoma

CXCR4 Inhibition Modulates Tumor Microenvironment and Robustly Inhibits Growth of B16-OVA Melanoma

December 2017
59th Annual Meeting of the American Society for Hematology (ASH)
X4P-001: A Novel Molecularly-Targeted Oral Therapy for WHIM Syndrome

November 2017
Society for Immunotherapy of Cancer (SITC) Annual Meeting
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T Cell Infiltration in Human Metastatic Melanoma

Efficacy and Mechanism of Action of CXCR4 Inhibition in B16 OVA Melanoma Model

October 2017
2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
A Phase 1 Dose Finding Study of X4P-001 (An Oral CXCR4 Inhibitor) and Axitinib in Patients with Advanced Renal Cell Carcinoma

September 2017
European Society of Medical Oncology 2017 Congress
A Phase 1 Dose Finding Study of X4P-001 (An Oral CXCR4 Inhibitor) and Axitinib in Patients with Advanced Renal Cell Carcinoma

November 2016
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Anti-tumor activity of X4P-001 in RCC with VEGF inhibitor

April 2016
American Association of Cancer Research (AACR) Annual Meeting 2016
MDSC Trafficking and Function in RCC by CXCR4 in the Presence of a VEGF-R Antagonist is Dependent on HIF-2α Express